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1007MP-121 Tissue Factor Elicits Thrombln Generetlon in Human 
Atheroeclerotic Plaques 
Pier Angelica Merlini, Maurizio Ferrario, Ezio Bramucci, Luigi Angoli, Alessandra 
Repetto, Umborto Canosi, Diego Ardissino, Cardiology, Policlinico San Matteo, Pavia, 
Italy, Cardiology,, Ospedale Niguarda, Milano, Italy, 
Background: Tissue Factor (TF, the initiator of blood coagulation) is more concentrated 
in coronary atherosclerotic plaques of patients (pts) with acute coronary syndromes 
(ACS) than in coronary plaques obtained from pts with stable angina pectoris (AP). How- 
ever, it is not clear whether this difference is associated with an in vivo increased throm- 
botic response to plaque rupture. The aim of the study was to evaluate the thromboganic 
potential of coronary plaques of pts with either ACS or stable AP, by measuring the local 
thrombin generation under basel conditions and after plaque rupture obtained by direc- 
tional coronary atherectomy (DCA). 
Methods: We studied 40 consecutive pts undergoing DCA: 22 pts with stable AP, 18 pts 
with ACS (12 with unstable AP, 6 with AMI). Blood samples were directly obtained, by a 
specially designed sampling catheter, proximally and distally to the coronary atheroscle- 
rotic plaque, both before and after the procedure. Plasma levels of prothrombin fragment 
1+2 (F1+2, a marker of thrombin generation) have been quantified by double antibody 
redioimmunoassay. 
Results: 
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Stable AP ACS p 
N= 22 N= 18 
Before DCA 
F1 +2 proximal 0.95 (0.78-1.87) 1.16 (0.86-1.49) ns 
F1+2 distal 1.00 (0.7-2.0) 1.50 (1.15-2.07) 0.0045 
Change -0.065 (-0.22-0.15) 0.37 (0.04-0.63) 0.0021 
After DCA 
F1+2 proximal 1.06 (0.86-1.39) 1.03 (0.99-1.68) ns 
F1+2 distal 0.97 (0.77-1.24) 1.31 (1.04-2.02) 0.027 
Change 0.01 (-0.06-0.14) 0.25 (0.02-0.42) 0.036 
Data are expressed as nrool/L; medians and interquartile ranges are reported. 
Conclusion: TF-dch plaques of pts with ACS are associated with a local increase in 
thrombin generation not detected in pts with stable AP, both under baseline conditions 
and after disruption by DCA. This data suggest a link between plaque composition and 
thrombogenicity, invivo. 
9:12 a.m. 
1007MP-122 Increased Circulating Tissue Factor and Blood 
Thrombogeniclty in Type-2 Diabetes 
Antonia Sambola. James Hathcock, Julio Osende, Yale Nemerson, Valentin Fuster, Jill 
Crandall, Juan Jose Badimon, Mount Sinai School of Medicine, New York, New York. 
Background: Several studies suggest a role for circulating tissue factor activity (TF-AcT) 
in atherothrombotic diseases. Type-2 Diabetes Mellitus (T2DM) is associated with a high 
rate of thrombotic omplications. We have previously shown an increase in the blood 
thrombogenicity (BT) in poorly controlled T2DM patients. Improvements in glycamic con- 
trol were associated with decreases in BT. Our objective in this study was to investigate 
1) whether T2DM is associated with increased circulating TF-AcT and 2) if an improve- 
ment in glycemic control is correlated with TF-AcT levels. 
Methods: Poorly controlled T2DM patients (n=36) maintaining their current hypoglyce- 
mic therapies, were randomized into diet modification plus troglitazona or diet modifica- 
tion plus placebo for 3 months. Cimulating TF-AcT was determined using a modification 
of a previously described technique, in which an immobilized antibody was used to cap- 
ture solubilized TF. TF-AcT was determined by measuring FXa generation. BT was 
assessed by the area of platalet-thrombus formation in the Badimon perfusion chamber. 
Improvement in glycamic control was considered a decreased HBAlc~- 0.5. 
Results: T2DM patients showed a significantly higher circulating TF-AcT plasma level, 
both at baseline and after treatment (370±161 vs 286±163 FXa (pM/min), p=0.0001) than 
healthy volunteers (211:t:60, FXa (pM/min), p=0.0001, n=t5). Patients with improvement 
in glycemic control showed a significant reduction in circulating TF activity (362~135 vs 
243±74 FXa (pM/min), p=0.0001), independent of the treatment group. A similar pattam 
was observed in BT (15.445±1130 vs 12072±596 pm/mm2, p=0.01). The reduction in 
HbAlc was significantly correlated to the reduction in TF-AcT levels (p=0.014). 
Conclusions: Our data indicate 1) high levels of circulating TF-AcT are present in T2DM 
patients, 2) changes in BT are associated with circulating TF-AcT levels in patients with 
T2DM. 3) Improvement in the glycamic control was associated with decreased TF-AcT 
levels. These findings suggest that the hyperthrombotic state associated with T2DM may 
be mediated by high levels of TF-AcT and these observations may help to develop future 
therapies in T2DM patients. 
9:24 a.m. 
1007MP-123 Simvsetatin and Pravaststin Inhibit the Synthesis of 
Tissue Factor In Smooth Muscle Cells In Vitro 
Plinio Cirill0, Paolo Golino, Psolo Calabrb, Massimo Regni, Lavinia Forte, Salvatore De 
Rosa, Massimo Chiariello, Division of Cardiology, University of Naples =Federico I1", 
Naples,/ta/y 
Background: Tissue factor (TF), a key initiator of blood coagulation, is widely expressed 
in atherosclerotic plaques, where it represents a major determinant of plaque thromboge- 
nicity. Statins reduce the incidence of acute coronary events, even in patients with nor- 
real cholesterol plasma levels. Methods: To verity whether statins reduce TF expression 
in smooth muscle cells (SMCs), SMCs from rabbit aortas, made quiescent by serum dep- 
rivation, were pretreated with either simvastatin (S; 5 pg/ml), pravastatin (P; 5 IJg/ml), or 
placebo. SMCs were stimulated for 30 min with lipopolysaccharide (LPS, 50 I~g/ml), a 
stimulus able to induce TF expression. TF activity was measured by a chromogenic 
assay and TF-mRNA levels were evaluated by a semi-quantitative RT-PCR. Results: 
LPS induced a significant TF protein expression, as compared to unstimulated cells (con- 
trol). Both simvastatin and pravastatin completely inhibited TF expression (*= p<0.01 vs 
LPS). 
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TF-mRNA levels increased significantly after LPS to 3.5±0.3 fold with respect to unstimu- 
lated cells, while they did not change significantly in cells pretreatred with S or P (1.1 ±0.1 
and 1.2±0.1 fold, respectively, as compared to their respective controls). Conclusion: S 
and P both reduce TF m-RNA and protein expression in SMCs stimulated with LPS, 
probably by inhibiting TF-mRNA transcription. This phenomenon might partly explain the 
benefical effects of statins in patients with coronary atherosclerosis. 
9:36 a.m. 
1007MP-124 Tissue Factor Expression Is Increased in Cardiac 
Transplant Recipients Who Develop Cardiac Transplant 
Arteriopathy 
Michael H. Yen, Guy Piikington, Norman Ratiiff, Patrick M McCarthy, James B. Young, 
Randall C. Starling, Guy M. Chisotm, Marc S. Penn, The ClevelandC/inic Foundation, 
Cleveland, Ohio. 
Background: We have demonstrated that oxidant stress upregulates tissue factor (TF) 
activity in smooth muscle (SMC) end endothelial cells (EC) by an antioxidant inhibitable 
mechanism. These data, along with the observations that (i) fibrin deposition and oxidant 
stress predict transplant arteriopathy (TA) and that (ii) TA progression may be inhibited 
by entioxidants, lead us to hypothesize that TF could play a role in TA. 
Methods: We developed a TF scoring index for TF expression in the arterioles in right 
heart biopsies (RHB). We studied 63 consecutive patients who underwent routine RHB 
and surveillance angiography >2 years (n=35), <2 years (n=28) after transplant. 
Results: Our data demonstrate that the TF score is predictive of TA. We found no corre- 
lation between TF expression and RHB rejection score. RHB specimens from patients 
without TA were more likely to have a low TF score; similarly specimens from patients 
with TA were more likely to have a high TF score (Table, p=0.005). TF score from biopsy 
specimens from patients within 2 years after transplant had a positive predictive value of 
89% and a negative predictive value of 100%. 
Conclusion: Our data demonstrate a correlation between increased TF expression and 
the development of TA. TF causes increased local thrombin production leading to (i) 
microvascular thrombosis, (ii) SMC proliferation, and (iii) EC activation. Furthermore, our 
data suggests that TF could be the target of antioxidant herapy, as well as future thera- 
pies directed at TA. 
>2 years (n=35) < 2 years (n=28) 
TA TF Low TF High TF Low TF High 
No (%) 78.9 21.1 87.5 12.5 
Yes (%) 31.3 68.9 0 100 
9:48 a.m. 
1007MP-125 Inhibitory Effect of C-Rseotive Protein on the Release of 
Tissue Factor Pathway Inhibitor From Human 
Endothelial Cells: Reversal by Low Molecular Weight 
Heparin 
Shaker A. Mousa, Jeffrey M. Bozarth, DuPont, Wilmington, Delaware. 
Elevated C-reactive protein (CRP) is associated with a higher risk of cardiac events in 
patients with acute coronary syndrome. Elevated CRP levels has been shown to promote 
the expression of tissue factor in monocytes, which may lead to fibrin deposition and 
JACC 
microcirculatory disturbances. However, the possible effects of CRP on vascular cells are 
not known. In the present investigation, the effects of CRP and hepadn derivatives on the 
release of tissue factor pathway inhibitor (TFPI) from human umbilical vein endothelial 
(HUVE) cells were examined. Methods: Confluent HUVE cells were resuspended and 
plated in 48 welt plate. Ceils were attached to fibronectin for 3 hours, washed and fresh 
medium with and without CRP, different LMWH or heparin molecular weight (HMW) frac- 
tions were added. TFPI released in the medium was measured using specific total TFPI 
immunoassay. Results: CRP demonstrated a potent inhibitory effect on TFPI release. In 
contrast, heparin demonstrated a potent stimulatory effect on TFPI release. The degree 
of TFPI release was shown to be dependent on the HMW distribution, with minimal to no 
effect at 3,000 dalton and maximal at 8,000-12,000 dalton. Furthermore, LMWH contain- 
ing relatively higher HMW fractions demonstrated greater potency. LMWH effectively 
reversed the inhibitory effects of CRP on TFPI release from HUVEC. These findings sup- 
port the hypothesis that CRP may play direct role in promoting hypercoaguable state that 
is correctable by LMWH. 
The Effect of CRP on TFPI Release from Human 
Endothelial Cells (T = 4 hours) 
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1007MP-126 Oxygen Free Radicals Induce a Procoagulant State in 
Endothelial Cells by Inhibiting Tissue-Factor Pathway 
Inhibitor 
Orlando Piro, Paolo Golino, Massimo Ragni, Annalisa Scognamiglio, Giovanni Cimmino, 
Filomena Botticella, Massimo Chiadello, University Federico II, Naples, Italy 
Background: Tissue factor pathway inhibitor (TFPI) is the natural inhibitor of tissue factor 
procoagulant activity. 
Methods: To verify if oxygen free radicals (OR) may affect TFPI activity and expression, 
endothelial cells were incubated with xanthine (X, 20 mM)/xanthine oxidase (XO, 0.4 U/ 
ml) for 5 min, a system generating OR. TFPI activity was measured in supernatants by 
chromogenic assay. TFPt mRNA was analyzed by northern blot 2 and 4 hrs after OR 
exposure. Controls included unstimulated cells and cells exposed to either X or XO. To 
verify a direct effect of OR on TFPI structure and binding to Factor Xa (FXa), recombi- 
nant TFPI (5 ug) exposed to OR in vitro (X, 20 raM/XO, 0.4 U/ml), was subjected to 
Western Blot analysis and ligand dot blot analysis with filter-immobilized FXa. 
Results: TFPI activity (expressed as % of the activity of normal rabbit plasma) was 
decreased by OR exposure (3±1%) with respect to unstimulated cells; p<0.05 vs con- 
trols,n=9. X or XO alone had no effect. Northern blot showed no differences in TFPI 
mRNA levels with respect to controls. A significant degradation of TFPI exposed to OR 
with respect to controls was evident (western blot Figure A). This resulted in a decreased 
ability of TFPI binding to FXa (ligand dot blot Figure B). 
Conclusions: OR induce a procoagulant state in endothelial cells by altering TFPI struc- 
ture, resulting in inhibition of TFPI binding to Factor Xa and loss of activity. This phenom- 
enon might have important consequences during reperfusion of post-ischemic 
myocardium. 
b, ll: tG'~O X XO 
A 
logical Method. Von Willebrand factor antigen (ELISA) and fibdnolytic potential 
(plasminogen activator inhibitor (PAl-l) antigen and tPA antigen), were also assessed. 
During follow-up (median 7 years), 197 patients had a first cardiovascular event (nonfatal 
MI, cardiac death, stroke, angina or congestive heart failure). Risk ratios (RR) versus 
lowest quartile were determined by multivariate Cox models, adjusting for age, hyperten- 
sion, diabetes, smoking and total cholesterol. Higher levels of Fibrinogen (FIF) and von 
Willebrend Factor, and PAl-1 and tPA antigen were associated with significantly 
increased CVD events. 
Conclusion: In a prospective evaluation of Framingham subjects with no prior clinical 
CVD, higher levels of prothrombotic factors - Fibrinogen and Von Willebrand Factor and 
impaired fibrinolytic potential (increased PAl-1 and tPA antigen) confer increased CVD 
risk. Measurement of these factors may improve risk assessment and facilitate selection 
of individuals for preventive therapy with the increasing number of effective anti-throm- 
botic agents. 
Comparison of highest to lowest quartile 
RR (95% CI) p-value 
Fibrinogen (FIF) 2.05 (1.15-3.65) 0.01 
Fibrinogen (Clauss) 1,14 (0.72-1.81) 0.57 
PAl-1 antigen 1.76 (1.09-2.90) 0.02 
tPA antigen 2.08 (t ,19-3.62) 0.01 
vWF antigen 1.57 (1.01-2,43) 0.04 
10:24 a.m. 
10:12 a.m. 
1007MP-127 HemostaUc Predictors of Cardiovascular Disease: 
Prospective Evaluation of the Framingham Offspring 
Study 
Geoffrey H. Toiler, Joseph Massaro, James E. Muller, Daniel Levy, Murray A. Mittleman, 
Izabela Lipinska, DaLi Feng, Christopher O'Donnell, Peter W. Wilson, Ralph B. 
D/~gostino, Royal North Shore Hospital, Sydney, Australia, Boston University School of 
Medicine, Boston, Massachusetts. 
Background: Since thrombosis plays a major role in cardiovascular disease (CVD), we 
determined whether hemostatic factors predicted future CVD events in subjects with no 
pdor known CVD. 
Methods: We prospectively studied 3213 subjects (mean age 54 years, 55% 
females)from the Offspdng Cohort of the Framingham Heart Study. Fibrinogen was mea- 
sured by the Clauss functional assay and the Functional Intact Fibdnogen (FIF)lmmuno- 
1007MP-128 Attenuation of Migration of Vascular Smooth Muscle 
Cells by Overexpression of Plasminogen Activator 
Inhibitor Type 1 
Michael G. Haves, Burton E. Sobel, Douglas J. Taatjes, Mercedes Rincon, David J. 
Schneider, University of Vermont, Burlington, Vermont. 
Background: Acute coronary syndromes are generally precipitated by rupture of vulner- 
able plaques. A thin, relatively acellular cap overlaying a necrotic lipid core characterizes 
vulnerable plaques. We have implicated ecreased vascular smooth muscle cell (VSMC) 
migration as one factor predisposing to plaque vulnerability. Elevated arterial content of 
plasminogen activator inhibitor type-1 (PAl-l) has been associated with increased dsk of 
plaque rupture. VSMC migration depends on cell surface expression of ptasminogen 
activators. PAl-1 is the pdmary physiologic inhibitor of plasminogen activators. Thus, we 
sought to determine whether increased expression of PAl-1 decreases VSMC migration. 
Methods: Constitutive, VSMC-specific overexpression of PAl-1 was induced in trans- 
genic mice with the use of the SM22(x promoter. VSMC migration was characterized in a 
well - insert micropore system. Matrigel was used as the extrecellular matrix (2 ~m thick- 
ness) and rat platelet-derived growth factor-BB was used as a chemoattractant. Migra- 
tion was quantified with laser scanning cytometry. 
Results: Immunohistochemical analysis of aortic tissue demonstrated increased PAl-1 in 
transgene positive mice compared with transgene negative Uttermates. VSMC (50,000 
cells) were seeded and migration through Matdgel was quantified after 20 hours. Migra- 
tion was consistently attenuated with transgene positive VSMC (4,459 ± 1313 [SD] 
VSMC from transgene positive mice and 7,323 ± 822 VSMC from transgene negative 
mice, p=0.03). Similar significant differences were seen with cells from 3 pairs of litter. 
mates. 
Conclusion: Thus, selective overexpression of PAl-1 in VSMC attenuates their migration 
and may potentiate volution of VSMC-poor atherosclerotic plaques that are particularly 
prone to rupture. 
10:36 a.m. 
1007MP-129 Transforming Growth Factor-b Regulation of 
Plasminogen Activator Inhibitor-1 Gene Expression at 
the 4G/5G Polymorphism 
John A. Schoenhard, Douglas E. Vaughan, Vanderbilt University Medical Center, 
Nashville, Tennessee. 
Background: Clinical studies have demonstrated that circulating levels of plasminogen 
activator inhibitor-1 (PAl-l) are strongly influenced by genotype at an insertion / deletion 
polymorphism describing alleles containing either four or five sequential guanine bases 
(4G or 5G, respectively) at -575 bp in the PAl-1 promoter. However, the molecular mech- 
anisms underlying allele-selective regulation of PAI*I expression remain poorly under- 
stood. We studied the mechanisms by which transforming growth tactor-~ (TGF-~,) 
regulates PAl-1 expression at the site of the 4G / 5G polymorphism. 
Methods: Transcdptional activation was assessed using PAl-1 promoter (-804 to +76 bp) 
/ luciferase reporter constructs in transfected HepG2 cells. 
Results: TGF-~ induced PAl-1 promoter activity independent of genotype (4G vs. 5G: 
14.2- vs. 13.4-fold at 250 pM TGF-I~; EC50 = 11.2 vs. 9.9 pM TGF-~). Although two 
Smad-binding elements flank the 4G / 5G polymorphism, neither Smad3.nor Smad4 
overexpression yielded allele-selective regulation of PAl-1 promoter activity. Rather, 
Smad3 induced the 4G allele by 9.7-fold and the 5G allele by 8.9-fold, while Smad4 
induced both alleles by 2.9-fold. TGF-~ treatment following Smad4 overexpression 
induced both alleles by 5.8-fold, but had no effect on Smad3-induced expression. Muta- 
tion of the PAl-1 promoter's proximal E-box (-569 to -564 bp) reduced TGF-13, Smad3, 
and Smad4 mediated induction of both 4G and 5G alleles by more than 50% by prevent- 
ing synergistic interactions between activated Smads and E-box binding bHLH transcrip- 
tion factors such as TFE3. However, no such effects were observed following mutation of 
the E-box which overlaps the 4G / 5G polymorphism. 
Conclusion: These results confirm that TGF-13 strongly induces PAl-1 promoter activity 
